The Patent Finder
SH

Shionogi & Co., Ltd.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

171 patents currently held

38 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Sep 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
31
Ending by 2030
Sep 2027
Next term end
123
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 25 to 27, 2026 · next Dec 25
  • 1 fee due Jan 21, 2027
    The maintenance fee for Humanized PCRV Antibody Having Anti-Pseudomonal Activity (US 9,085,611) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
  • 2 fees due Feb 18 to 27, 2027 · next Feb 18
  • 1 fee due Mar 15, 2027
    The maintenance fee for (3S,11aR)-6-[(PHENYLMETHYL)OXY]-3-Methyl-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-Dione OF THE FORMULA P-9 AND/OR (3S,11aR)-6-[(PHENYLMETHYL)OXY]-8-Bromo-3-Methyl-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-Dione OF THE FORMULAP-10 (US 9,133,216) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
  • 2 fees due Apr 6 to 22, 2027 · next Apr 6
  • 3 fees due May 7 to 14, 2027 · next May 7
  • 4 fees due Jun 1 to 24, 2027 · next Jun 1
  • 4 fees due Jul 14 to 30, 2027 · next Jul 14
  • 4 fees due Aug 4 to 25, 2027 · next Aug 4
  • 7 fees due Sep 1 to 29, 2027 · next Sep 1
  • 2 fees due Oct 19 to 28, 2027 · next Oct 19
  • 1 fee due Nov 5, 2027
    The maintenance fee for Heterocycle Derivatives Having Trka Inhibitory Activity (US 10,640,495) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 4 of the patents on this record were granted since Aug 18, 2026
  • 5 terms have ended since Aug 18, 2026

What they patent

The 5 largest of its 123 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 7,378,423Pyrimidine Compound and Medical Use Thereof
In force
 · High confidence
In forceHigh confidence
US 8,071,633Pharmaceutical Composition for Treating Spinocerebellar Ataxia
In force
 · High confidence
In forceHigh confidence
US 8,232,4014-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor
In force
 · Medium confidence
In forceMedium confidence
US 8,993,763Sulfonamide Derivative Having PGD2 Receptor Antagonistic Activity
In force
 · Medium confidence
In forceMedium confidence
US 8,202,879Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity
In force
 · High confidence
In forceHigh confidence
US 8,765,9651-(2,3-Dihydroxypropyl)-4-OXO-3-[(PHENYLMETHYL)OXY]-1,4-Dihydro-2-Pyridinecarboxylic Acid of the Formula P-6 And/Or Methyl 1-(2,3-Dihydroxypropyl)-4-OXO-3-[(PHENYLMETHYL)OXY]-1,4-Dihydro-2-Pyridinecarboxylate of the Formula P-7
In force
 · High confidence
In forceHigh confidence
US 8,940,9124-OXO-3-[(PHENYLMETHYL)OXY]-4H-PYRAN-2-Carboxylic Acid
In force
 · High confidence
In forceHigh confidence
US 8,981,1292-(2-Hydroxy-2-Phenylethyl)-3-[(PHENYLMETHYL)OXY]-4H-PYRAN-4-ONE of the Formula P-3 And/Or 2-[(E)-2-Phenylethenyl]-3-[(PHENYLMETHYL)OXY]-4H-PYRAN-4-ONE of the Formula P-4
In force
 · High confidence
In forceHigh confidence
US 9,012,650SUBSTITUTED (3S, 11aR)-N-[(2,4-Difluorophenyl)METHYL]-6-OXY-3-Methyl-5,7-Dioxo-2,3,5,7,11,11a-HEXAHYDRO[1,3]OXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-8-Carboxamides OF FORMULA (I) USEFUL AS HIV AGENTS
In force
 · Medium confidence
In forceMedium confidence
US 9,133,216(3S,11aR)-6-[(PHENYLMETHYL)OXY]-3-Methyl-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-Dione OF THE FORMULA P-9 AND/OR (3S,11aR)-6-[(PHENYLMETHYL)OXY]-8-Bromo-3-Methyl-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-Dione OF THE FORMULAP-10
In force
 · High confidence
In forceHigh confidence
10 of 171 patents shown.
Pro members see all 171.
Pro members: see all 171 patents
Also on record, not counted in the 171: 38 patents in force now held by others · 221 patents ended · 78 applications pending · 178 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited